Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14665867 | 0.82 | NOS3 (0.36) | BACE1 | |
| SCHEMBL20621031 | 0.78 | MBOAT4 (0.32) | — | |
| SCHEMBL28521553 | 0.73 | APP (0.40) | BACE1 | |
| SCHEMBL14525220 | 0.72 | HTR1A (0.32) | HTR1A | |
| SCHEMBL1787026 | 0.72 | IRAK4 (0.32) | BACE1 | |
| SCHEMBL31254281 | 0.71 | RXRA (0.32) | — | |
| SCHEMBL14659609 | 0.71 | DUT (0.32) | — | |
| SCHEMBL4546535 | 0.71 | HTR6 (0.35) | HTR1A | |
| SCHEMBL3929716 | 0.71 | CCR1 (0.43) | HTR1A | |
| SCHEMBL15968790 | 0.70 | MEN1 (0.39) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054428-A1 | NOVEL PYRIMIDINE DERIVATIVES 965 | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| US-20090054428-A1 | NOVEL PYRIMIDINE DERIVATIVES 965 | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| WO-2009010794-A1 | 2,4-DIAMINO-PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054428-A1 | NOVEL PYRIMIDINE DERIVATIVES 965 | EPHB4, EPHB1, EPHB3 | BACE1 3906/4885HTR1A 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.